Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.
The IT Business Partner (ITBP) serves as the technical lead for our international IT operations as well as scientific divisions located in our Seattle campus. The ITBP is the liaison between our international sites / scientific divisions and Center IT for IT priorities and initiatives. In support of scientific program leadership and research priorities, the ITBP will lead and be responsible for IT strategy, planning, timelines, budgeting and driving the IT needs for the program. The ITBP will work across IT to develop creative, technology-driven solutions to solve complex problems and identify new opportunities for innovation and optimization. The ITBP is also responsible for guiding and mentoring IT staff and consultants in Fred Hutch’s scientific settings. The ideal candidate will be a strong self-starter and skilled communicator, thrive in a fast-paced environment, have a demonstrated ability to solve technical challenges, and drive coordination between technical teams and business stakeholders. This position will report to the Portfolio Supervisor within the Project Management Office.
The scope of International IT operations includes but is not limited to:
- Global Oncology, a cross-divisional program at Fred Hutchinson Cancer Research Center reporting to the Director’s office, has a mission to generate cancer research that has global impact, and support the development of research capacity and clinical care to reduce the burden of cancer in low- and middle-income countries. A cornerstone of the program is a decade-long alliance with the Uganda Cancer Institute (UCI) in Kampala, where Fred Hutch maintains a 25,000 square foot research, clinical care, and training facility, while other global cancer research activities are being pursued in China and elsewhere.
- The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV/AIDS. The Network conducts all phases of clinical trials, from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Headquartered at Fred Hutch, the HVTN is an international partnership of research scientists, clinical trial sites, laboratories, funders, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine. The HVTN partners with more than 30 clinical trial sites on five continents. Fred Hutch has a 10,000-square foot laboratory in Cape Town, South Africa, referred to as the Cape Town HVTN Immunology Laboratory (CHIL) serving as a base for upcoming vaccine trials in South Africa and throughout the region. The South African clinical and laboratory teams reside across South Africa but primarily operate within Cape Town, Johannesburg and surrounding neighborhoods.
- The Women’s Health Initiative (WHI) launched in 1991 with a $625 million grant from the National Heart, Lung, and Blood Institute, one of the National Institutes of Health. As one of the largest U.S. prevention studies of its kind, the WHI is an ethnically and geographically diverse study of women. It was designed to address risk factors for cardiovascular disease, cancer and osteoporosis — the most frequent causes of death, disability and poor quality of life in postmenopausal women. At its inception, the WHI consisted of an observational study and clinical trials, with over 161,000 women enrolled at 40 prestigious research centers nationwide. The initial trials tested the effects of postmenopausal hormone therapy, a low-fat diet, and calcium and vitamin D supplements on risk of heart disease, fractures, breast cancer and colorectal cancer. Since then, WHI investigators, their colleagues and other independent investigators have leveraged program resources to initiate nearly 300 separately funded research projects. The massive WHI database and biospecimen repository is available to all researchers. Scientists have published more than 1800 papers using WHI data.